LU90719I2 - Pioglitazone ou un sel pharmaceutiquement acceptable de celui-ci - Google Patents

Pioglitazone ou un sel pharmaceutiquement acceptable de celui-ci

Info

Publication number
LU90719I2
LU90719I2 LU90719C LU90719C LU90719I2 LU 90719 I2 LU90719 I2 LU 90719I2 LU 90719 C LU90719 C LU 90719C LU 90719 C LU90719 C LU 90719C LU 90719 I2 LU90719 I2 LU 90719I2
Authority
LU
Luxembourg
Prior art keywords
pioglitazone
pharmaceutically acceptable
acceptable salt
salt
pharmaceutically
Prior art date
Application number
LU90719C
Other languages
English (en)
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11683488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90719(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of LU90719I2 publication Critical patent/LU90719I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
LU90719C 1985-01-19 2001-01-24 Pioglitazone ou un sel pharmaceutiquement acceptable de celui-ci LU90719I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP808585 1985-01-19

Publications (1)

Publication Number Publication Date
LU90719I2 true LU90719I2 (fr) 2001-03-26

Family

ID=11683488

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90719C LU90719I2 (fr) 1985-01-19 2001-01-24 Pioglitazone ou un sel pharmaceutiquement acceptable de celui-ci

Country Status (28)

Country Link
US (1) US4687777A (fr)
EP (1) EP0193256B1 (fr)
JP (1) JPS61267580A (fr)
KR (1) KR920010046B1 (fr)
CN (1) CN1003934B (fr)
AR (1) AR240698A1 (fr)
AT (1) ATE41931T1 (fr)
AU (1) AU572719B2 (fr)
BR (1) BR1100325A (fr)
CA (1) CA1277323C (fr)
CS (1) CS407991A3 (fr)
DE (2) DE3662689D1 (fr)
DK (2) DK21986A (fr)
ES (1) ES8705886A1 (fr)
FI (1) FI81098C (fr)
GR (1) GR860124B (fr)
HK (1) HK3692A (fr)
HU (1) HU196795B (fr)
IE (1) IE58928B1 (fr)
LU (1) LU90719I2 (fr)
LV (1) LV5779B4 (fr)
MX (1) MX9202933A (fr)
MY (1) MY102016A (fr)
NL (1) NL300038I2 (fr)
NO (1) NO163857C (fr)
PT (1) PT81859B (fr)
SG (1) SG105691G (fr)
ZA (1) ZA86203B (fr)

Families Citing this family (276)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK305884A (da) * 1983-06-24 1984-12-25 Yamanouchi Pharma Co Ltd Phenoxyderivat, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
WO1988009661A1 (fr) * 1987-06-10 1988-12-15 Pfizer Inc. Derives d'oxazolidine-2-one a usage d'agents hypoglycemiques
GB8713861D0 (en) * 1987-06-13 1987-07-15 Beecham Group Plc Compounds
EP0295828A1 (fr) * 1987-06-13 1988-12-21 Beecham Group Plc Composés chimiques
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US4798835A (en) * 1987-12-02 1989-01-17 Pfizer Inc. dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB8919417D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US4997948A (en) * 1989-10-27 1991-03-05 American Home Products 5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
AU651571B2 (en) † 1990-02-09 1994-07-28 Pharmacia & Upjohn Company Use of insulin sensitizing agents to treat hypertension
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
EP0454501B1 (fr) * 1990-04-27 2001-09-05 Sankyo Company Limited Dérivés de benzylidène thiazolidines, leur préparation et leur utilisation pour l'inhibition de péroxydes lipidiques
GB9023584D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
US5158966A (en) * 1991-02-22 1992-10-27 The University Of Colorado Foundation, Inc. Method of treating type i diabetes
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
SK109993A3 (en) * 1991-04-11 1994-12-07 Upjohn Co Thiazolidinedione derivatives producing and use thereof
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
CZ181493A3 (en) * 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
JP2845743B2 (ja) * 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
CZ283339B6 (cs) * 1993-09-15 1998-03-18 Sankyo Company Limited Použití thiazolidinových derivátů pro výrobu léčivého přípravku pro léčení zhoršené tolerance glukosy pro zabránění nebo zpoždění nástupu diabetes mellitus nezávislé na inzulinu
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
WO1995024400A1 (fr) * 1994-03-08 1995-09-14 American Home Products Corporation Derives de thiazolidinedione utilises comme agents anti-hyperglycemiques
US6251928B1 (en) 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
RU2137770C1 (ru) * 1994-10-20 1999-09-20 Ниппон Кемифар Ко., Лтд. Производные хинолина
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
WO1996035688A1 (fr) * 1995-05-08 1996-11-14 Nippon Chemiphar Co., Ltd. Derives de 2,4-thiazolidinedione ou d'oxazolidinedione et agent hypoglycemique
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IL118778A (en) * 1995-07-03 1999-07-14 Sankyo Co Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
EP0783888A1 (fr) 1995-12-26 1997-07-16 Sankyo Company Limited Utilisation de la troglitazone et de thiazolidinediones apparentées dans la fabrication d'un médicament destiné au traitement et la prévention de l'ostéoporose
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
AU2381397A (en) * 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
CA2257284C (fr) * 1996-05-31 2005-10-04 Sankyo Company Limited Remede pour maladies auto-immunes
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
ATE399545T1 (de) * 1996-11-08 2008-07-15 Nippon Chemiphar Co Mittel zur verringerung der eigeweidefette
JP2001514663A (ja) * 1997-03-12 2001-09-11 エスモンド，ロバート ダブリュー． アルツハイマー病を処置または予防するための方法
US5908859A (en) * 1997-08-11 1999-06-01 Eli Lilly And Company Benzothiophenes for inhibiting hyperlipidemia
HUP9902721A2 (hu) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
WO1999030739A1 (fr) * 1997-12-16 1999-06-24 Sankyo Company, Limited Remede contre la leucemie
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
EP1143953A3 (fr) * 1998-11-20 2002-02-06 Genentech, Inc. Methode d'inhibition de l'angiogenese
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
DE60035271D1 (en) 1999-04-28 2007-08-02 Inst Med Molecular Design Inc Pyrimidincarbonsäurederivate
CN1321153A (zh) * 1999-07-01 2001-11-07 杰龙公司 端粒酶抑制剂及其使用方法
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
US7390824B1 (en) * 1999-09-07 2008-06-24 Bristol-Myers Squibb Company Method for treating diabetes employing an aP2 inhibitor and combination
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
CO5200844A1 (es) 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
ES2156574B1 (es) * 1999-11-18 2002-02-01 Vita Invest Sa Nuevos derivados de tiazolidindiona como agentes antidiabeticos
RU2256661C2 (ru) 1999-12-03 2005-07-20 Киото Фармасьютикал Индастриз, Лтд. Производные тетрагидроизохинолина и их соли и фармацевтическая композиция на их основе
EP1741445B1 (fr) 2000-01-21 2013-08-14 Novartis AG Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabetiques
US6958355B2 (en) * 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6680387B2 (en) * 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
CN1426402A (zh) * 2000-04-25 2003-06-25 杏林制药株式会社 噻唑烷二酮衍生物的新颖的稳定晶体及其制法
WO2002024689A1 (fr) * 2000-09-21 2002-03-28 Aryx Therapeutics Composes a base d'isoxazolidine pouvant etre utilises pour le traitement du diabete, de l'hyperlipidemie et de l'atherosclerose
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
EP1354602B1 (fr) * 2000-12-26 2006-10-04 Sankyo Company, Limited Compositions medicinales contenant un diuretique et un agent renforcant la resistance a l'insuline
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CA2434488A1 (fr) * 2001-01-26 2002-08-01 Harry R. Davis Combinaisons d'acide nicotinique et de derives de ce dernier, inhibiteur(s) d'absorption de sterols et traitements de conditions vasculaires
DK1385548T3 (da) * 2001-01-26 2007-09-10 Schering Corp Kombinationer af sterolabsorptionsinhibitor(er) med (et eller flere) kardiovaskulære midler til behandling af vaskulære tilstande
EP1785144A3 (fr) * 2001-01-26 2007-05-23 Shering Corporation Combinaisons de séquestrant(s) d'acides biliaires, et inhibiteur(s) d'absorption de stérol, et traitements pour les indications vasculaires
JP4711600B2 (ja) * 2001-01-26 2011-06-29 シェーリング コーポレイション シトステロール血症の処置のための置換アゼチジノン化合物の使用
SI1413331T1 (sl) * 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
US20020147184A1 (en) * 2001-01-26 2002-10-10 Schering Corporation Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
EA007485B1 (ru) * 2001-02-24 2006-10-27 Берингер Ингельхайм Фарма Гмбх Унд Ко. Кг Производные ксантина, способ их получения, фармацевтическая композиция на их основе и способ ее получения
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US20030045553A1 (en) * 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
US20060047000A1 (en) * 2001-04-24 2006-03-02 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
ATE480236T1 (de) * 2001-04-25 2010-09-15 Takeda Pharmaceutical Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans
HUP0400091A2 (hu) * 2001-04-26 2004-06-28 Léciva, a.s. Eljárás antidiabetikus hatású pioglitazon előállítására
HUP0400023A2 (hu) * 2001-05-29 2004-04-28 Kyoto Pharmaceutical Industries, Ltd. Új heterociklusos származékok és gyógyászati alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
BR0209711A (pt) * 2001-05-29 2004-11-03 Kyoto Pharma Ind Composto heterocìclico e seu uso medicinal
CA2456034A1 (fr) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7132415B2 (en) * 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
ATE411018T1 (de) * 2001-09-21 2008-10-15 Schering Corp Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
WO2003026586A2 (fr) * 2001-09-28 2003-04-03 Teva Pharmaceutical Industries Ltd. Chlorhydrate de pioglitazone
US20050101638A1 (en) * 2002-11-08 2005-05-12 Webb Randy L. Combination of organic compounds
US20050187258A1 (en) * 2001-12-20 2005-08-25 Ben-Zion Dolitzky Hydrogenation of precursors to thiazolidinedione antihyperglycemics
AU2002366812A1 (en) * 2001-12-20 2003-07-09 Teva Pharmaceutical Industries Ltd. Hydrogenation of precursors to thiazolidinedione antihyperglycemics
ITRM20020016A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
WO2003062427A1 (fr) * 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Methode de criblage de medicaments ameliorant la resistance a l'insuline
US7015345B2 (en) * 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
KR100450700B1 (ko) * 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
WO2003105809A1 (fr) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Comprimes multicouche contenant des thiazolidinediones et des biguanides et procedes de production desdits comprimes
AU2003272072A1 (en) 2002-07-16 2004-02-02 Cadila Healthcare Limited A process to prepare pioglitazone via several intermediates.
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2003260813A1 (en) * 2002-09-12 2004-04-30 Themis Laboratories Private Limited Improved process for preparation of thiazolidinedione derivatives
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
AU2003272504A1 (en) 2002-09-20 2004-04-08 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
CA2504878A1 (fr) * 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption du cholesterol pour le traitement de la demyelination
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN100439361C (zh) 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2004108721A1 (fr) * 2003-04-01 2004-12-16 Sun Pharmaceutical Industries Limited Procede servant a preparer 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione
ES2219180B1 (es) * 2003-05-09 2006-03-01 Medichem, S.A. Compuesto intermedio util para la preparacion de pioglitazona.
US20050059708A1 (en) * 2003-05-13 2005-03-17 Karel Pospisilik Processes for making thiazolidinedione derivatives and compounds thereof
EP1640374A1 (fr) * 2003-05-13 2006-03-29 Synthon B.V. Sels de pioglitazone tels que le sulfate de pioglitazone, et leurs compositions pharmaceutiques et leurs procédés d'utilisation
US7230016B2 (en) * 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
US7718377B2 (en) * 2003-05-29 2010-05-18 Kyoto Pharmaceutical Industries, Ltd. Insulin resistance curative and method of screening the same
NZ577031A (en) 2003-05-30 2010-09-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-CO inhibitors
EP1506967B1 (fr) 2003-08-13 2007-11-21 Takeda Pharmaceutical Company Limited Inhibiteurs de dipeptidyl peptidase.
WO2005021542A2 (fr) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Procede pour la preparation de pioglitazone
WO2005021543A1 (fr) * 2003-09-03 2005-03-10 Biocon Limited Sel d'acide phosphorique de 5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2, 4-thiazolidinedione
EP1699777B1 (fr) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidylpeptidase
WO2005027967A1 (fr) * 2003-09-17 2005-03-31 Kaname Kawasugi Composition medicinale
EP1680189A2 (fr) * 2003-11-05 2006-07-19 Schering Corporation Combinaisons de modulateurs lipidiques et d'azetidinones substituees et traitements d'affections vasculaires
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP1716144A2 (fr) * 2004-02-20 2006-11-02 Synthon B.V. Procedes pour produire de la pioglitazone et composes issus de ces procedes
MXPA06010571A (es) * 2004-03-15 2007-02-16 Takeda Pharmaceutical Inhibidores de dipeptidil peptidasa.
WO2005092382A1 (fr) * 2004-03-29 2005-10-06 Sankyo Company, Limited Agent thérapeutique pour diabète contenant un agent améliorant la résistance à l’insuline
US7161756B2 (en) * 2004-05-10 2007-01-09 Tandberg Data Storage Asa Method and system for communication between a tape drive and an external device
US20060025478A1 (en) * 2004-07-27 2006-02-02 Keisuke Inoue Medicine for prevention or treatment of diabetes
TW200608967A (en) * 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
WO2006022428A1 (fr) * 2004-08-26 2006-03-02 Takeda Pharmaceutical Company Limited Remède contre le diabète
WO2006035459A1 (fr) * 2004-09-28 2006-04-06 Morepen Laboratories Limited Procede ameliore pour la production de derives de thiozolidinediones et de leurs precurseurs
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP1828192B1 (fr) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Inhibiteurs de dipeptidyle peptidase
US8017633B2 (en) * 2005-03-08 2011-09-13 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
US20070269486A1 (en) * 2005-03-14 2007-11-22 Conor Medsystems, Llc. Methods and Devices for Reducing Tissue Damage After Ischemic Injury
KR20080025662A (ko) * 2005-03-18 2008-03-21 오키드 케미칼즈 앤드 파마수티컬즈 리미티드 신규 티로신 유도체
WO2006117654A1 (fr) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Procedes de preparation de pioglitazone ou de sels de ce compose
CN101272805A (zh) * 2005-07-12 2008-09-24 第一三共株式会社 包含PPARγ激动剂的药物组合物
WO2007029062A2 (fr) * 2005-07-29 2007-03-15 Orchid Research Laboratories Limited Derives de pyridine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
ME02005B (fr) * 2005-09-14 2012-08-31 Takeda Pharmaceuticals Co Inhibiteurs de la dipeptidyl peptidase permettant de traiter le diabete
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
WO2007054896A1 (fr) 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Procede de preparation de sel hemicalcique d’acide (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoique
TW200730173A (en) * 2005-12-16 2007-08-16 Sankyo Co Pharmaceutical composition enhancing production of adiponectin
PL2001469T3 (pl) * 2006-03-16 2012-10-31 Metabolic Solutions Dev Co Llc Analogi tiazolidynodionu
EP2001470A2 (fr) * 2006-03-16 2008-12-17 Metabolic Solutions Development Company Therapies d'association d'analogues de la thiazolidinedione
MX356584B (es) 2006-03-16 2018-06-05 Metabolic Solutions Dev Co Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
EP1852108A1 (fr) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
ES2376396T3 (es) 2006-06-26 2012-03-13 Amgen Inc. Método para tratar aterosclerosis.
KR100791399B1 (ko) 2006-09-06 2008-01-07 동우신테크 주식회사 염산 피오글리타존의 제조방법
CA2662084A1 (fr) 2006-09-07 2008-03-13 Nycomed Gmbh Polytherapie contre le diabete sucre
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US20080182880A1 (en) * 2006-09-28 2008-07-31 Mailatur Sivaraman Mohan Pioglitazone composition
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US20100098641A1 (en) * 2006-12-13 2010-04-22 William Baker Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction
WO2008075380A2 (fr) * 2006-12-21 2008-06-26 Ind-Swift Laboratories Limited Procédé de préparation de dérivés de thiazolidine
EP2016076A2 (fr) * 2007-01-22 2009-01-21 Teva Pharmaceutical Industries Ltd. Formes polymorphes d'hydrobromure de rosiglitazone et leurs procédés de préparation
RS51592B (sr) * 2007-02-01 2011-08-31 Takeda Pharmaceutical Company Limited Čvrsti preparat koji sadrži alogliptin i pioglitazon
EP1988091B1 (fr) 2007-02-07 2015-06-10 Kyowa Hakko Kirin Co., Ltd. Composés tricycliques
WO2008105326A1 (fr) * 2007-02-28 2008-09-04 Ohara Chemical Industries, Ltd. Procédé de production d'un dérivé de 2-imino-4-thiazolidinone et d'un dérivé de 2,4-thiazolidinedione
AR065670A1 (es) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
US8093236B2 (en) * 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
PL2068909T3 (pl) 2007-03-30 2012-09-28 Ambrx Inc Modyfikowane polipeptydy fgf-21 i ich zastosowanie
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CN105250285B (zh) 2007-04-11 2019-09-06 奥默罗斯公司 预防和治疗成瘾的组合物和方法
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008259342B2 (en) 2007-06-04 2014-07-10 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
MY159075A (en) 2007-07-26 2016-12-15 Amgen Inc Modified lecithin-cholesterol acyltransferase enzymes
EP3542801A1 (fr) * 2007-08-17 2019-09-25 Boehringer Ingelheim International GmbH Dérivés de la purine destinés à être utilisés dans le traitement de maladies associées à fab
NZ597381A (en) 2007-09-14 2013-03-28 Metabolic Solutions Dev Co Llc Thiazolidinedione analogues for the treatment of diabetes and inflammatory diseases
WO2009035997A2 (fr) * 2007-09-14 2009-03-19 Cara Therapeutics, Inc. Hétérocycles benzo-fusionnés
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
RU2366421C2 (ru) * 2007-11-01 2009-09-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтический состав для лечения диабета
US20090118514A1 (en) * 2007-11-06 2009-05-07 Raghupathi Reddy Anumula Processes for preparing pioglitazone and its pharmaceutically acceptable salts
JP5334422B2 (ja) * 2008-02-13 2013-11-06 株式会社トクヤマ ５−｛４−［２−（５−エチル−２−ピリジル）エトキシ］ベンジル｝−２−イミノ−４−チアゾリジノンの製造方法
JP5197063B2 (ja) * 2008-02-21 2013-05-15 株式会社トクヤマ ２−ブロモ−３−｛４−［２−（５−エチル−２−ピリジル）エトキシ］フェニル｝プロピオン酸メチルの製造方法
PE20140960A1 (es) * 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2310367A1 (fr) * 2008-04-28 2011-04-20 ERREGIERRE S.p.A. Procédé de préparation de 4-ý2-(5-éthyl-2-pyridyl)éthoxy¨nitrobenzène et de pioglitazone
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
CA2726917C (fr) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP2321341B1 (fr) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
JP5559689B2 (ja) 2008-08-06 2014-07-23 協和発酵キリン株式会社 ３環系化合物
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
DK2324126T3 (da) 2008-08-12 2014-06-16 Zinfandel Pharmaceuticals Inc FREMGANGSMÅDE TIL IDENTIFICERING AF Alzheimers SYGDOMSRISIKOFAKTORER
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CN103816158A (zh) * 2008-08-15 2014-05-28 勃林格殷格翰国际有限公司 用于治疗fab-相关疾病的嘌呤衍生物
CN102112444A (zh) * 2008-09-02 2011-06-29 株式会社德山 脱溴化氢化抑制剂
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
JP5441913B2 (ja) * 2008-10-10 2014-03-12 株式会社トクヤマ カルボニルオキシ化合物の製造方法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP5473303B2 (ja) * 2008-12-01 2014-04-16 株式会社トクヤマ ２−ブロモ−３−｛４−［２−（５−エチル−２−ピリジル）エトキシ］フェニル｝プロピオン酸メチルの製造方法
US20100144140A1 (en) * 2008-12-10 2010-06-10 Novellus Systems, Inc. Methods for depositing tungsten films having low resistivity for gapfill applications
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20110110766A (ko) * 2009-01-20 2011-10-07 가부시끼가이샤 도꾸야마 2-브로모-3-｛4-［2-（5-에틸-2-피리딜）에톡시］페닐｝프로피온산메틸의 탈브롬화 수소화를 억제하는 방법
JP2010208957A (ja) * 2009-03-06 2010-09-24 Tokuyama Corp 結晶構造を有する５−｛４−［２−（５−エチル−２−ピリジル）エトキシ］ベンジル｝−２−イミノ−４−チアゾリジノン及びその製造方法
CN106692144A (zh) 2009-03-11 2017-05-24 奥默罗斯公司 预防和治疗成瘾的组合物和方法
US8686009B2 (en) * 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
AU2010266018B2 (en) 2009-06-25 2014-01-09 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
BR112012011237A2 (pt) 2009-11-13 2019-09-24 Univ Tokyo agente terapêutico e profilático para diabetes
EP2504002B1 (fr) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Traitement de patients diabétiques génotypés par des inhibiteurs de dpp-iv tels que la linagliptine
DK2513070T3 (en) 2009-12-15 2018-01-22 Cirius Therapeutics Inc PPAR-sparing thiazolidinedione salts for the treatment of metabolic disorders
US10429384B2 (en) 2010-01-22 2019-10-01 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
US20140088027A1 (en) 2010-03-30 2014-03-27 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20200028498A (ko) 2010-06-24 2020-03-16 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
WO2012028934A1 (fr) 2010-09-01 2012-03-08 Lupin Limited Composition pharmaceutique contenant de la metformine et de la pioglitazone
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN103501783A (zh) 2011-01-10 2014-01-08 金帆德尔制药股份有限公司 用于治疗阿尔茨海默病的方法和药物产品
WO2012153312A1 (fr) 2011-05-11 2012-11-15 Ranbaxy Laboratories Limited Procédé pour la purification de pioglitazone
HUE061596T2 (hu) 2011-07-15 2023-07-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
KR20140051998A (ko) 2011-08-03 2014-05-02 교와 핫꼬 기린 가부시키가이샤 디벤조옥세핀 유도체
WO2013068486A1 (fr) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes pour le diagnostic et le traitement de l'infertilité masculine
CN104220460A (zh) 2011-12-08 2014-12-17 安姆根有限公司 激动人lcat抗原结合蛋白和它们在疗法中的用途
WO2013088255A1 (fr) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Promédicaments de composés amine secondaires
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2638898A1 (fr) 2012-03-16 2013-09-18 Sanovel Ilac Sanayi ve Ticaret A.S. Formulation de pioglitazone et metformine avec différents profils de libération
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
AU2013340478B2 (en) 2012-11-05 2018-08-23 Commissariat A L'energie Atomique Et Aux Energies Alternatives (Cea) Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a STAT5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
US8969581B2 (en) 2013-03-14 2015-03-03 Deuterx, Llc 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
US20140275138A1 (en) * 2013-03-15 2014-09-18 Cba Pharma, Inc. Method and products for treating diabetes
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
US9815777B2 (en) 2013-09-22 2017-11-14 Jiva Pharma, Inc. Metformin salts to treat Type2 diabetes
AU2014331812B2 (en) 2013-10-09 2019-01-17 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
WO2015068156A1 (fr) 2013-11-05 2015-05-14 Ben-Gurion University Of The Negev Research And Development Authority Composés pour le traitement du diabète et des complications pathologiques qui en résultent
WO2015109037A1 (fr) 2014-01-15 2015-07-23 Deuterx, Llc Méthodes de traitement de troubles neurologiques, métaboliques et autres à l'aide de pioglitazone énantiopure enrichie en deutérium
EP3110449B1 (fr) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Utilisation médicale d'un inhibiteur de dpp-4
KR101606547B1 (ko) * 2014-06-02 2016-03-28 김동연 공항 탑승객 위치조회시스템
CN107108710B (zh) 2014-10-24 2022-02-15 百时美施贵宝公司 修饰的fgf-21多肽及其用途
WO2016071727A1 (fr) 2014-11-04 2016-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes pour la prévention et le traitement de la glomérulonéphrite rapidement progressive
EP3025707A1 (fr) 2014-11-27 2016-06-01 Arven Ilac Sanayi Ve Ticaret A.S. Comprimé multicouche comprenant de la metformine et du pioglitazone
DK3468604T3 (da) 2016-06-08 2021-04-19 Support Venture Gmbh Farmaceutiske kombinationer til behandling af cancer
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
BR112019003006A2 (pt) 2016-08-17 2019-05-14 Support-Venture Gmbh uso de uma combinação farmacêutica e kit para prevenir ou tratar perda auditiva
TR201620309A2 (tr) 2016-12-30 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇
WO2018185098A1 (fr) 2017-04-04 2018-10-11 Strekin Ag Procédés de prévention ou de traitement de maladies ophtalmiques
WO2019154893A1 (fr) 2018-02-08 2019-08-15 Strekin Ag Compositions pharmaceutiques orales à libération prolongée pour la prévention ou le traitement de la perte auditive
WO2019154895A1 (fr) 2018-02-08 2019-08-15 Strekin Ag Formulation en gel pour la prévention ou le traitement de la perte auditive
WO2019173230A1 (fr) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Stratégie de dosage d'aripiprazole
AU2019300135A1 (en) 2018-07-13 2021-01-28 Kinarus Ag Combinations of PPAR agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
CN111875598B (zh) * 2020-05-23 2023-10-10 白银京宇新药业有限公司 一种吡格亚胺的制备方法
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
WO2022034031A1 (fr) 2020-08-11 2022-02-17 Kinarus Ag Procédés de prévention ou de traitement de covid-19 et de maladies ou troubles viraux associés
IL301793A (en) 2020-09-30 2023-05-01 Duality Biologics Suzhou Co Ltd Anticancer compound and method for its preparation and use
JP6925072B1 (ja) * 2020-12-07 2021-08-25 株式会社Dr.Cherry 毛髪改善のための組成物
EP4385502A1 (fr) 2022-12-15 2024-06-19 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulation pharmaceutique comprenant de la metformine, de la pioglitazone et un inhibiteur de sglt-2
EP4385501A1 (fr) 2022-12-15 2024-06-19 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulation pharmaceutique comprenant de la linagliptine, de la pioglitazone et un inhibiteur de sglt-2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途

Also Published As

Publication number Publication date
CS407991A3 (en) 1992-04-15
FI860232L (fi) 1986-07-20
NL300038I2 (nl) 2001-05-01
HU196795B (en) 1989-01-30
NO163857B (no) 1990-04-23
HK3692A (en) 1992-01-17
IE58928B1 (en) 1993-12-01
LV5779A4 (lv) 1996-12-20
KR920010046B1 (ko) 1992-11-13
JPH0566956B2 (fr) 1993-09-22
GR860124B (en) 1986-05-19
LV5779B4 (lv) 1997-04-20
CA1277323C (fr) 1990-12-04
ES8705886A1 (es) 1987-05-16
NO163857C (no) 1990-08-01
FI81098B (fi) 1990-05-31
HUT41775A (en) 1987-05-28
DK171614B1 (da) 1997-02-24
IE860107L (en) 1986-07-19
MY102016A (en) 1992-02-29
DK21986A (da) 1986-07-20
BR1100325A (pt) 2000-06-27
AU572719B2 (en) 1988-05-12
DE3662689D1 (en) 1989-05-11
ES550986A0 (es) 1987-05-16
DE10199018I1 (de) 2001-07-12
ZA86203B (en) 1987-09-30
KR860005811A (ko) 1986-08-13
MX9202933A (es) 1992-06-30
NO860141L (no) 1986-07-21
EP0193256B1 (fr) 1989-04-05
ATE41931T1 (de) 1989-04-15
DE10199018I2 (de) 2006-02-02
EP0193256A1 (fr) 1986-09-03
DK21986D0 (da) 1986-01-17
PT81859A (en) 1986-02-01
SG105691G (en) 1992-02-14
AU5246786A (en) 1986-07-24
FI860232A0 (fi) 1986-01-17
US4687777A (en) 1987-08-18
PT81859B (pt) 1988-05-27
CN86100411A (zh) 1986-07-16
JPS61267580A (ja) 1986-11-27
CN1003934B (zh) 1989-04-19
AR240698A1 (es) 1990-09-28
FI81098C (fi) 1990-09-10

Similar Documents

Publication Publication Date Title
LU90719I2 (fr) Pioglitazone ou un sel pharmaceutiquement acceptable de celui-ci
LU88791I2 (fr) Gemcitabine ou un sel pharmaceuticallement acceptable de celle-ci
NO865141D0 (no) Fremgangsmaate for desinfisering av en overflate.
ZA872439B (en) Pharmaceutically acceptable salts
DK292986D0 (da) Thiazoler
NO171628C (no) Dreiehode
DK321088A (da) Thiazolidindionderivater
ES2015249B3 (es) Procedimiento de fabricacion de un condimento.
BR8803271A (pt) Acoplamento giratorio
FI865169A7 (fi) Flytbaeddsvaermegenerator med foerbaettrad anordning foer avlaegsnande av aska och foer aotervinning av vaerme.
IT1217955B (it) Errice ruotante
FI860226A0 (fi) Spiralelementband med skyddade kanter.
EP0245058A3 (en) Herbicidal heterocyclic sulfonamides
FI852632L (fi) Foerfarande foer oeverfoering av filtrerad massa med skivfilter och skivfilter.
NO872583D0 (no) Syklonseparator.
FI860225A0 (fi) Banformningsvira med foerstaerkta kanter.
FI901087A7 (fi) Atsolidiinidionijohdannaisia
ES540869A0 (es) Maquina astilladora
GB8521467D0 (en) S(-)2-(4-carboxy-3-hydroxybutyl)cylcopent-2-ene-1-one
DK566586A (da) Pencilliner
PT83542A (fr) Cursseur pour la ficelle d:un cerf-volant
KR890006547U (ko) 앵글용 v홈 절단기
NL187203C (nl) Rotatie-inlegger.
BR8806693A (pt) Ceifadeira rotativa
DK389385D0 (da) Indsats til oral brug